The Ultimate Guide to Blister Packaging Types in Pharma

The major types of blister packaging in pharma include PVC, PVDC-coated PVC (using PVDC Solid State Sealing Equipment), ACLAR-laminated, Alu-Alu cold-form, child-resistant, and face-seal blister pack. These blister types protect pharmaceutical products from moisture, oxygen, and light. The correct blister packaging type depends on the API's sensitivity and regulatory stability requirements. In 2023, the packaging market for pharmaceuticals reached USD 22.2 billion.

Key Takeaways

• Choose blister packaging based on how sensitive your drug is to moisture, oxygen, and light.
• PVC is cheap for stable drugs, but sensitive drugs need stronger barriers like PVDC, ACLAR, or Alu-Alu.
• Always test your chosen packaging with the actual drug and follow regulations to ensure safety and compliance.

PVC Blister Packaging

Material Composition and Barrier Performance

Polyvinyl chloride (PVC) serves as the foundational material for many packaging options in drug manufacturing. The thermoforming process shapes PVC film into blister cavities that hold each dose. For a standard 250 µm thick uncoated PVC film at 38°C and 90% relative humidity, the moisture vapor transmission rate (WVTR) measures approximately 3.1 g/m²·day. When the same material forms into finished pharmaceutical blisters, the WVTR decreases to 0.0011 g/(pkg·24h). This moderate moisture barrier supports many stable drug formulations.

Cost Profile and Typical Applications

Among common blister packaging materials, PVC ranks as the most economical option. The thermoformed blister pack serves as a standard low-cost solution for high-volume production lines. Manufacturers often use this blister pack for tablets that do not require enhanced protective layers. The simple thermoformed blister packaging process and abundant supply chain maintain low per-unit costs. Multiple thermoformed blister packs fit easily into secondary packaging.

Limitations for Sensitive APIs

Despite its cost benefits, PVC blisters present a significant drawback for sensitive APIs. The material's inherent moisture barrier falls short for hygroscopic active ingredients. Over time, moisture permeates through the walls, compromising product stability. Additionally, the blister packaging lacks light-blocking properties, making it unsuitable for photolabile compounds. These limitations drive the need for alternative material types when handling moisture-sensitive or light-sensitive formulations.

PVDC-Coated PVC Blister Packaging

How PVDC Solid State Sealing Equipment Improves Moisture Barrier

A thin layer of polyvinylidene chloride (PVDC) applied to PVC film dramatically improves moisture protection. PVDC solid state sealing equipment applies this coating with precision and consistency. The coating creates a denser structure that slows water vapor transmission. PVDC solid state sealing equipment ensures uniform coverage across the entire film surface. This uniformity matters because gaps in the coating allow moisture to pass through. PVDC solid state sealing equipment also supports faster production speeds compared to older coating methods.

The data above shows a reduction of approximately 0.5 to 3 g/m²/day. Newer duplex PVC/PVDC films achieve even lower rates. A 40 g/m² PVDC coating reduces MVTR from 0.12 to 0.08 g/m²/day. PVDC solid state sealing equipment makes these results possible on a commercial scale.

Cost and Application Fit

PVDC-coated PVC costs more than plain PVC. The added material and processing steps raise the per-unit price. However, this blister packaging option remains cheaper than ACLAR-laminated or Alu-Alu formats. Manufacturers choose PVDC-coated PVC for moderate moisture-sensitive drugs. Common applications include vitamins, analgesics, and certain antibiotics. The blister pack fits standard thermoforming lines with minimal changes.

When PVDC Is Not Enough

PVDC-coated PVC fails for highly hygroscopic APIs. The moisture barrier cannot handle extreme humidity conditions. Light-sensitive compounds also need additional protection. In these cases, manufacturers must select ACLAR laminates or Alu-Alu cold-form blister packs. Each alternative offers stronger barrier properties at a higher cost.

ACLAR-Laminated Blister Packaging

Composition and Moisture Barrier Strength

ACLAR is a polychlorotrifluoroethylene (PCTFE) film. Manufacturers laminate this film onto PVC to create a high-performance blister packaging material. The fluoropolymer layer provides an exceptional moisture barrier. A typical 30 µm ACLAR film achieves a moisture vapor transmission rate (MVTR) of 0.008 g/m²/day. This value is far lower than standard PVC or PVDC-coated PVC. The laminate structure blocks water vapor effectively even under high humidity conditions.

Light Protection and Use Cases

ACLAR film offers moderate light protection. It blocks UV light in the 200–400 nm range. This property makes the blister pack suitable for photolabile drugs. Common applications include proton pump inhibitors, antibiotics, and certain hormones. The pharmaceutical industry relies on ACLAR laminates for drugs that need both moisture and light protection. The material also resists chemical interactions with sensitive formulations.

Cost Considerations and Limitations

ACLAR-laminated blister packs cost significantly more than PVC or PVDC options. The fluoropolymer film drives up material expenses. Processing also requires specialized equipment and careful handling. These blister packs may not suit cost-sensitive, high-volume products. Manufacturers should weigh the barrier benefits against budget constraints. For highly sensitive APIs, the added cost often justifies the protection.

Alu-Alu Cold-Form Blister Packaging

Cold-Forming Process and Material Structure

Cold-formed alu-alu packaging builds each cavity from a multilayer aluminum-aluminum laminate. A stamping press deforms the foil at room temperature, so the material stretches into deep pockets without heat. This process creates blister cavities with sharp, well-defined walls. The laminate typically contains three layers.

The industry has largely converged on 45 µm as a practical minimum for pharmaceutical CFF, with 60 µm used where deeper pockets or higher barrier assurance is required.

Maximum Barrier Performance

The metallic core delivers the strongest moisture barrier of any blister format. Cold-formed aluminum foil laminates achieve an oxygen transmission rate of ≤0.5 cm³/(m²·24h·0.1MPa). This near-zero OTR reflects the fully metallic barrier on both the cavity and lidding sides. The package blocks oxygen ingress and protects oxygen-sensitive formulations when formed and sealed correctly. No polymer film matches this level of protection.

Cost, Tooling, and Applications

Alu-Alu blister packs cost more than PVC or ACLAR options. The foil laminate drives material expenses upward. Tooling also demands higher investment because each product needs custom forming dies. Manufacturers select this blister pack for highly hygroscopic drugs, oxygen-sensitive biologics, and products requiring extended shelf life. The format suits low-volume, high-value pharmaceutical products where protection outweighs unit cost.

Child-Resistant and Face-Seal Blister Packaging

Child-Resistant Designs and Compliance Drivers

Child-resistant blister packaging protects young children from accidental ingestion of dangerous medications. The Poison Prevention Packaging Act (PPPA) requires child-resistant designs for most oral prescription drugs. Manufacturers achieve this through push-through designs that demand two simultaneous actions. A child cannot easily open these blister packs. Adults, however, can access the medication with moderate effort. The pharmaceutical industry must also meet senior-friendly requirements under the PPPA. These rules ensure that older adults can still open the packaging without excessive difficulty.

Face-Seal Construction and Benefits

Face-seal blister packaging uses a different sealing method. The lidding material seals only to the face of the blister cavity, not to the areas between cavities. This design creates cold seal blister wallets with a peel-back opening mechanism. Cold seal blister wallets allow patients to peel the lidding film away from the cavity. Cold seal blister wallets offer several advantages. They provide easy access for elderly patients. They also support unit-dose labeling and reduce medication errors. The construction works well with tablets and capsules.

Applications and Trade-Offs

Child-resistant and face-seal formats serve distinct markets. Child-resistant blister packaging suits opioids, anticoagulants, and other high-risk drugs. Face-seal designs fit hospitals, long-term care facilities, and compliance packaging programs. Both formats cost more than standard PVC blisters. Tooling and material expenses run higher. Manufacturers must balance safety requirements against production costs. The right choice depends on the drug's risk profile and the patient population.

Comparing Types of Blister Packaging by API Sensitivity

Selecting the right blister packaging type requires a clear understanding of how each API responds to environmental stress. Moisture, oxygen, and light represent the three primary threats to drug stability. Different APIs show different sensitivity profiles. A systematic comparison helps manufacturers match the material to the molecule.

Hygroscopic Drugs

Hygroscopic drugs absorb moisture from the surrounding environment. This absorption triggers chemical degradation, changes in crystal structure, or loss of potency. A drug that takes up water can become sticky, dissolve prematurely, or fail dissolution testing. The moisture barrier of the selected blister packaging directly controls how much water vapor reaches the API over the product's shelf life.

Standard PVC blisters offer a moderate moisture barrier. A 250 µm PVC film transmits water vapor at roughly 3.1 g/m²·day. This rate suits stable formulations. Hygroscopic APIs need stronger protection. PVDC-coated PVC reduces moisture transmission to approximately 1.0–1.5 g/m²·day at 40 gsm coating weight. This improvement helps moderately hygroscopic drugs. Highly hygroscopic APIs demand even greater protection.

ACLAR-laminated blisters provide a moisture barrier of 0.008–0.02 g/m²·day. This value represents a hundredfold improvement over standard PVC. Alu-Alu cold-form blister packs deliver the strongest barrier of all. The metallic core blocks moisture almost completely. Oxygen transmission rates fall below 0.5 cm³/(m²·24h·0.1MPa). For a highly hygroscopic API, Alu-Alu cold-form represents the safest choice.

Manufacturers should review the API's equilibrium moisture content and critical relative humidity. These two parameters define the acceptable moisture exposure limit. The chosen blister packaging must keep internal humidity below that threshold for the entire shelf life. Stability data at accelerated conditions (40°C/75% RH) and long-term conditions (25°C/60% RH) guide this decision.

Moisture- and Light-Sensitive Drugs

Some APIs degrade through two pathways at once. Moisture triggers hydrolysis, and light triggers photolysis. These dual-sensitive drugs require a blister format that blocks both threats. The material must provide a strong moisture barrier and act as a light shield.

ACLAR-laminated blister packs address both concerns. The PCTFE film blocks UV light in the 200–400 nm range. The same film delivers a moisture barrier of 0.008–0.02 g/m²·day. This combination makes ACLAR a strong candidate for photolabile, moisture-sensitive compounds. Proton pump inhibitors, certain antibiotics, and some hormones fall into this category.

Alu-Alu cold-form blister packs offer complete light protection. The opaque aluminum foil blocks all wavelengths. No light reaches the API. The metallic structure also provides the highest moisture barrier available. For a drug that degrades under both moisture and light, Alu-Alu cold-form is the most protective option.

PVDC-coated PVC does not block light. The film remains transparent. A manufacturer can add an opaque overcoat or use a pigmented film. These modifications increase cost and complexity. For dual-sensitive APIs, ACLAR or Alu-Alu formats usually make better economic sense.

The pharmaceutical industry often combines light protection with moisture protection in a single laminate. This approach simplifies the supply chain and reduces the number of packaging components. A well-designed blister pack for a dual-sensitive drug will specify the light transmission limit and the moisture vapor transmission rate as separate acceptance criteria.

Stable Drugs

Stable APIs do not degrade easily under normal storage conditions. These drugs tolerate moderate humidity and light exposure. Their formulations often include excipients that buffer against environmental stress. For these products, the blister packaging type serves a functional role rather than a protective one.

PVC blisters work well for stable drugs. The material costs the least among all options. It runs on standard thermoforming lines at high speed. Tablets and capsules that show no sensitivity to moisture or light fit this format perfectly. Vitamins, analgesics, and many over-the-counter pharmaceuticals fall into this group.

PVDC-coated PVC offers a middle ground. The added coating improves moisture protection at a modest cost increase. A manufacturer might choose this option for a stable drug that needs a small safety margin. The decision often depends on the target shelf life and the storage conditions in the destination market.

The table below summarizes the fit between API sensitivity and blister format.

Cost drives the final decision for stable drugs. A manufacturer will not pay for an Alu-Alu format when PVC meets all stability requirements. The excess barrier adds cost without adding value. Regulatory guidelines support this approach. They require sufficient protection, not maximum protection.

Stable drugs also benefit from simpler tooling and faster line speeds. PVC thermoforming runs at higher throughput than cold-form aluminum. The packaging line requires less capital investment. These factors reduce the total cost per unit. For high-volume pharmaceutical products, even a small cost difference per blister translates into significant annual savings.

A manufacturer should still confirm stability with the chosen format. Some APIs show unexpected sensitivity after long-term storage. A drug that passes six-month accelerated testing might fail at 24 months. The stability protocol must cover the full intended shelf life. Real-time data at the intended storage condition provides the final proof.

How to Spec the Right Blister Packaging in the Pharmaceutical Industry

Specifying the correct blister packaging for a drug product requires a structured approach. The process moves from data review to physical testing to regulatory confirmation. Each step builds on the previous one. A manufacturer who skips a step risks costly reformulation or market withdrawal. The pharmaceutical industry follows this sequence to ensure patient safety and product quality.

Review Stability Data First

The specification process begins with a thorough review of the API's stability profile. Stability data reveals how the drug substance responds to temperature, humidity, and light over time. This information defines the protective requirements for the chosen blister packaging. A manufacturer cannot select a material without this foundation.

The review should examine forced degradation studies. These studies expose the API to extreme conditions and identify its primary degradation pathways. Hydrolysis indicates moisture sensitivity. Photolysis indicates light sensitivity. Oxidation indicates oxygen sensitivity. Each pathway points to a specific barrier requirement.

Accelerated stability data at 40°C/75% RH provides early signals about moisture sensitivity. Long-term data at 25°C/60% RH confirms those signals over the intended shelf life. The manufacturer should compare the degradation rate under different humidity conditions. A steep increase in degradation at higher humidity confirms moisture sensitivity. This finding rules out standard PVC as a viable option.

The critical relative humidity of the API sets the upper limit for moisture exposure. The chosen blister packaging must maintain internal humidity below this threshold for the entire shelf life. The manufacturer calculates the required moisture vapor transmission rate based on this limit. The calculation considers the tablet weight, the headspace volume, and the desired shelf life. A higher barrier material allows a longer shelf life or a smaller package size.

Light sensitivity data comes from photostability studies conducted per ICH Q1B. These studies expose the API to defined light doses and measure degradation. A photolabile compound requires a blister format with light-blocking properties. The manufacturer must decide between UV-blocking films and fully opaque foils. This decision depends on the wavelength range that triggers degradation.

Oxygen sensitivity adds another dimension. Some APIs oxidize rapidly when exposed to air. The manufacturer must select a blister format with a low oxygen transmission rate. Alu-Alu cold-form blister packs provide the strongest oxygen barrier. Polymer films allow more oxygen ingress. The stability data determines whether a polymer film provides sufficient protection.

The stability review should also consider the drug product formulation. Excipients can buffer against moisture or light exposure. A coated tablet may tolerate more humidity than an uncoated one. The formulation scientist and the packaging engineer should review the data together. This collaboration ensures that the packaging specification matches the actual product needs.

Request Samples and Run Line Trials

After the stability review defines the barrier requirements, the manufacturer requests material samples from suppliers. These samples allow the packaging team to evaluate the material's physical properties. The team examines film thickness, seal strength, and forming characteristics. They also check the material's compatibility with the existing packaging line.

Line trials represent the next critical step. A line trial runs the candidate material on the actual production equipment. This test reveals how the material behaves under real operating conditions. The trial measures forming temperature windows, sealing parameters, and machine speed. It also identifies defects such as weak seals, incomplete forming, or film tearing.

The number of samples needed for a line trial depends on several factors. No universal standard exists for sample quantity. The manufacturer must justify the quantity based on process knowledge, equipment complexity, product variability, and risk. A fixed number from a protocol template does not apply to every situation.

There is no universal or typical sample quantity for blister packaging line trials. Neither FDA's CGMP nor Annex 15 prescribe a minimum number of conformance batches. The quantity must be justified using process knowledge, equipment complexity, product variability, risk, and the intended control strategy.

A manufacturer running a trial on a well-characterized line with a proven material might need fewer samples. A new material on a new line requires more extensive sampling. The goal is to demonstrate that the process produces consistent, high-quality blister packs. Statistical significance depends on the variability observed during the trial, not on a predetermined number.

The line trial should also test the sealing process. Seal integrity is the most critical quality attribute for any blister pack. A weak seal allows moisture to enter the cavity. The trial should include seal strength testing at multiple points across the web. It should also test the seal under stress conditions such as elevated temperature and humidity.

The trial protocol should define acceptance criteria before the trial begins. These criteria include seal strength minimums, forming depth tolerances, and visual defect limits. The team records all deviations and investigates their root causes. A successful trial meets all acceptance criteria and produces enough data to set the operating ranges for commercial production.

The manufacturer should also evaluate the material's performance on the filling and cartoning equipment. A material that forms well but jams the cartoner creates a new problem. The line trial should cover the entire packaging process from forming to cartoning. This holistic approach identifies integration issues early.

Test with the Specific API and Confirm Compliance

The final step moves from material testing to API-specific testing. The manufacturer fills the candidate blister packs with the actual drug product. These samples undergo stability testing under ICH conditions. The test measures the drug's potency, purity, and dissolution profile over time. The results confirm whether the chosen blister packaging provides adequate protection.

Compatibility testing forms the core of this step. The manufacturer must ensure that the packaging material does not interact with the drug substance. The table below lists the critical quality attributes for this assessment.

Material compatibility testing follows USP <661> and the European Pharmacopoeia. These standards define the tests required to confirm that the packaging material is suitable for pharmaceutical use. The tests examine the material's chemical composition and its potential to release harmful substances. A material that fails these tests cannot enter the market.

Extractables and leachables analysis follows ICH Q3E. Extractables are compounds that can migrate from the packaging material under extreme conditions. Leachables are compounds that actually migrate into the drug product under normal storage conditions. The manufacturer must identify and quantify both. A leachable that exceeds the safety threshold requires a material change or a toxicological risk assessment.

The API-specific stability study should run for at least six months under accelerated conditions. It should also include long-term data at the intended storage condition. The manufacturer compares the results to the stability data from the original packaging. A significant difference indicates that the new packaging does not provide equivalent protection. The team must then investigate the cause and adjust the specification.

Regulatory compliance adds another layer of requirements. The manufacturer must confirm that the chosen blister packaging meets all applicable regulations. These regulations vary by market. The FDA requires child-resistant packaging for most oral prescription drugs under the Poison Prevention Packaging Act. The EU requires similar protections under its own directives. A manufacturer selling in multiple markets must meet the strictest requirement.

The compliance review should also examine the supplier's quality systems. The supplier must provide a Drug Master File or a similar regulatory document. This file contains confidential information about the material's composition and manufacturing process. Regulatory agencies review this file during the drug approval process. A supplier without a Drug Master File may delay the approval timeline.

The final specification should document all test results and acceptance criteria. It should include the material type, the film thickness, the seal parameters, and the barrier properties. It should also reference the stability data that supports the choice. This document becomes the basis for quality control testing during commercial production.

The manufacturer should review the specification periodically. Changes in the supplier's manufacturing process can alter the material's properties. Changes in the drug formulation can alter its sensitivity profile. A periodic review ensures that the specification remains valid throughout the product lifecycle. This ongoing vigilance protects patients and maintains regulatory compliance.

The entire specification process takes time and resources. A manufacturer who rushes the process risks a failed stability study or a regulatory rejection. A manufacturer who follows the sequence builds a robust specification that supports the product for years. The investment in proper testing pays off in patient safety and commercial success.

Manufacturers must select the blister based on the API sensitivity profile instead of a default material. The comparison matrix serves as an initial filter. Stability data and line trials validate the choice. Regulatory compliance and total cost finalize the specification. The market confirms this trend. High-barrier blister packaging shows a projected 6–7 percent compound annual growth rate over five years toward approximately $30 billion by 2030.

FAQ

What role does blister packaging play for moisture-sensitive drugs?

It provides a critical barrier. Alu-Alu cold-form blister packaging offers the highest protection against moisture and oxygen ingress for sensitive APIs.

Why do manufacturers choose PVDC-coated PVC blister packs?

PVDC coating improves the moisture barrier significantly. It fits moderate-priority packaging needs where ACLAR or Alu-Alu costs remain too high.

Does blister packaging require child-resistant features?

Yes, regulations require it for most oral prescription drugs. The blister must combine child-resistance with senior-friendly access for adult usability.

Welcome to contact us, we will be dedicated to serving you!